| Literature DB >> 33727152 |
Xing Zhou1, Francesca Motta2, Carlo Selmi2, William M Ridgway3, M Eric Gershwin4, Weici Zhang5.
Abstract
The glycosylation of the fragment crystallizable (Fc) region of immunoglobulins (Ig) is critical for the modulation of antibody effects on inflammation. Moreover, antibody glycosylation may induce pathologic modifications and ultimately contribute to the development of autoimmune diseases. Thanks to progress in the analysis of glycosylation, more data are available on IgG and its subclass structures in the context of autoimmune diseases. In this review, we focused on the impact of Ig glycosylation in autoimmunity, describing how it modulates the immune response and how glycome profiles can be used as biomarkers of disease activity. The analysis of antibody glycosylation demonstrated specific features in human autoimmune and chronic inflammatory conditions, including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease and autoimmune liver diseases, among others. Within the same disease, different patterns are associated with disease severity and treatment options. Future research may increase the information available on the distinct glycome profiles and expand their potential role as biomarkers and as targets for treatment, ultimately favoring an individualized approach.Entities:
Keywords: Antibody; Autoimmune Diseases; Fc fragment; Glycosylation; Inflammation
Mesh：
Year: 2021 PMID： 33727152 PMCID： PMC8058319 DOI： 10.1016/j.autrev.2021.102804
Source DB: PubMed Journal: Autoimmun Rev ISSN： 1568-9972 Impact factor: 9.754